Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: Applications in evaluating novel therapeutic agents

Current Protocols in Pharmacology

Volumn , Issue SUPPL. 45, 2009, Pages

  Connolly, Denise C ^a   Hensley, Harvey H ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Bioluminescent imaging; Epithelial ovarian cancer (EOC); In vivo imaging; Magnetic resonance imaging; Metastasis; Orthotopic; Transgenic mice; Xenograft

Indexed keywords

CISPLATIN; EVEROLIMUS; GADOLINIUM PENTETATE; GREEN FLUORESCENT PROTEIN; LUCIFERASE; PACLITAXEL; RETROVIRUS VECTOR; VASCULOTROPIN; VIRUS T ANTIGEN;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIOLUMINESCENCE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL OVARY CANCER; EUTHANASIA; FLUORESCENCE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VIVO STUDY; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SURGICAL TECHNIQUE; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SPECIMEN HANDLING; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 66849128197     PISSN: 19348282     EISSN: 19348290     Source Type: Journal    
DOI: 10.1002/0471141755.ph1412s45     Document Type: Review

References (52)

1. Adams, A.T. and Auersperg, N. 1981. Transformation of cultured rat ovarian surface epithelial cells by Kirsten murine sarcoma virus. Cancer Res. 41:2063-2072.
2. Auersperg, N., Maines-Bandiera, S.L., and Dyck, H.G. 1997. Ovarian carcinogenesis and the biology of ovarian surface epithelium. J. Cell. Physiol. 173:261-265.
3. Bao, R., Connolly, D.C., Murphy, M., Green, J., Weinstein, J.K., Pisarcik, D.A., and Hamilton, T.C. 2002. Activation of cancer-specific gene expression by the survivin promoter. J. Natl. Cancer Inst. 94:522-528.
4. Callaghan, P. 1994. Principles of Nuclear Magnetic Resonance Microscopy. Oxford University Press, New York.
5. Choy, G., O'Connor, S., Diehn, F.E., Costouros, N., Alexander, H.R., Choyke, P., and Libutti, S.K. 2003. Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques 35:1022-1026, 1028-1030.
6. Clark-Knowles, K.V., Garson, K., Jonkers, J., and Vanderhyden, B.C. 2007. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp. Cell Res. 313:133-145.
7. Connolly, D.C., Bao, R., Nikitin, A.Y., Stephens, K.C., Poole, T.W., Hua, X., Harris, S.S., Vanderhyden, B.C., and Hamilton, T.C. 2003. Female mice chimeric for expression of the SV40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 63:1389-1397.
8. Coppola, D., Saunders, B., Fu, L., Mao, W., and Nicosia, S.V. 1999. The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res. 59:3264-3270.
9. Crum, C.P., Drapkin, R., Miron, A., Ince, T.A., Muto,M., Kindelberger,D.W., and Lee,Y. 2007. The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr. Opin. Obstet. Gynecol. 19:3-9.
10. Davies, B.R., Auersperg, N., Worsley, S.D., and Ponder, B.A. 1998. Transfection of rat ovarian surface epithelium with erb-B2/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo. Am. J. Pathol. 152:297-306.
11. Dickins, R.A., Hemann, M.T., Zilfou, J.T., Simpson, D.R., Ibarra, I., Hannon, G.J., and Lowe, S.W. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37:1289-1295.
12. Dinulescu, D.M., Ince, T.A., Quade, B.J., Shafer, S.A., Crowley, D., and Jacks, T. 2005. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11:63-70.
13. DiSaia, P.J., Morrow, M., Kanabus, J., Piechal, W., and Townsend, D.E. 1975. Two new tissue culture lines from ovarian cancer. Gynecol. Oncol. 3:215-219.
14. Dubeau, L. 1999. The cell of origin of ovarian epithelial tumors and the surface epithelium dogma: Does the emperor have no clothes? Gynecol. Oncol. 72:437-442.
15. Dutertre, M., Gouedard, L., Xavier, F., Long, W.Q., di Clemente, N., Picard, J.Y., and Rey, R. 2001. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Endocrinology 142:4040-4046.
16. Flesken-Nikitin, A., Choi, K.C., Eng, J.P., Shmidt, E.N., and Nikitin, A.Y. 2003. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63:3459-3463.
17. Fredrickson, T.N. 1987. Ovarian tumors of the hen. Environ. Health Perspect. 73:35-51.
18. Freedman, R.S., Pihl, E., Kusyk, C., Gallager, H.S., and Rutledge, F. 1978. Characterization of an ovarian carcinoma cell line. Cancer 42:2352-2359.
19. Fu, X. and Hoffman, R.M. 1993. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res. 13:283-286.
20. Godwin, A.K., Testa, J.R., Handel, L.M., Liu, Z., Vanderveer, L.A., Tracey, P.A., and Hamilton, T.C. 1992. Spontaneous transformation of rat ovarian surface epithelial cells: Association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J. Natl. Cancer Inst. 84:592-601.
21. Hamilton, T.C., Young, R.C., McKoy, W.M., Grotzinger, K.R., Green, J.A., Chu, E.W., Whang-Peng, J., Rogan, A.M., Green, W.R., and Ozols, R.F. 1983. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43:5379-5389.
22. Hamilton, T.C., Young, R.C., Louie, K.G., Behrens, B.C.,McKoy,W.M., Grotzinger, K.R., and Ozols, R.F. 1984. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 44:5286-5290.
23. Hensley, H., Quinn, B.A., Wolf, R.L., Litwin, S.L., Mabuchi, S., Williams, S.J., Williams, C., Hamilton, T.C., and Connolly, D.C. 2007. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol. Ther. 6:1717-1725.
24. Ioachim, H.L., Dorsett, B.H., Sabbath, M., and Barber, H.R. 1975. Electron microscopy, tissue culture, and immunology of ovarian carcinoma. Natl. Cancer Inst. Monogr. 42:45-62.
25. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M.J. 2008. Cancer statistics, 2008. CA Cancer J. Clin. 58:71-96.
26. Kananen, K., Markkula, M., Rainio, E., Su, J.G., Hsueh, A.J., and Huhtaniemi, I.T. 1995. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: Characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol. Endocrinol. 9:616-627.
27. Keri, R.A., Lozada, K.L., Abdul-Karim, F.W., Nadeau, J.H., and Nilson, J.H. 2000. Luteinizing hormone induction of ovarian tumors: Oligogenic differences between mouse strains dictates tumor disposition. Proc. Natl. Acad. Sci. U.S.A. 97:383-387.
28. Kiguchi, K., Kubota, T., Aoki, D., Udagawa, Y., Yamanouchi, S., Saga, M., Amemiya, A., Sun, F.X., Nozawa, S., Moossa, A.R., and Hoffman, R.M. 1998. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin. Exp. Metastasis 16:751-756
29. Kolfschoten, G.M., Pinedo, H.M., Scheffer, P.G., Schluper, H.M., Erkelens, C.A., and Boven, E. 2000. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol. Oncol. 76:362-368.
30. Kumar, T.R., Palapattu, G., Wang, P., Woodruff, T.K., Boime, I., Byrne, M.C., and Matzuk, M.M. 1999. Transgenic models to study gonadotropin function: The role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Mol. Endocrinol. 13:851-865.
31. Liu, J., Yang, G., Thompson-Lanza, J.A., Glassman, A., Hayes, K., Patterson, A., Marquez, R.T., Auersperg, N., Yu, Y., Hahn, W.C., Mills, G.B., and Bast, R.C. Jr. 2004. A genetically defined model for human ovarian cancer. Cancer Res. 64:1655-1663.
32. Mabuchi, S., Altomare, D.A., Connolly, D.C., Klein-Szanto, A., Litwin, S., Hoelzle, M.K., Hensley, H.H., Hamilton, T.C., and Testa, J.R. 2007. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 67:2408-2413.
33. Massazza, G., Tomasoni, A., Lucchini, V., Allavena, P., Erba, E., Colombo, N., Mantovani, A., D'Incalci, M., Mangioni, C., and Giavazzi, R. 1989. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int. J. Cancer 44:494-500.
34. Molpus, K.L., Koelliker, D., Atkins, L., Kato, D.T., Buczek-Thomas, J., Fuller, A.F. Jr., and Hasan, T. 1996. Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int. J. Cancer 68:588-595.
35. Orsulic, S., Li, Y., Soslow, R.A.,Vitale-Cross, L.A., Gutkind, J.S., and Varmus, H.E. 2002. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53-62.
36. Ozols, R.F., Louie, K.G., Plowman, J., Behrens, B.C., Fine, R.L., Dykes, D., and Hamilton, T.C. 1987. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem. Pharmacol. 36:147-153.
37. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55:74-108.
38. Rahman, N.A. and Huhtaniemi, I.T. 2001. Ovarian tumorigenesis in mice transgenic for murine inhibin alpha subunit promoter-driven Simian Virus 40 T-antigen: Ontogeny, functional characteristics, and endocrine effects. Biol. Reprod. 64:1122-1130.
39. Resnicoff, M., Ambrose, D., Coppola, D., and Rubin, R. 1993. Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab. Invest. 69:756-760.
40. Risma, K.A., Clay, C.M., Nett, T.M., Wagner, T., Yun, J., and Nilson, J.H. 1995. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc. Natl. Acad. Sci. U.S.A. 92:1322-1326.
41. Roby, K.F., Taylor, C.C., Sweetwood, J.P., Cheng, Y., Pace, J.L., Tawfik, O., Persons, D.L., Smith, P.G., and Terranova, P.F. 2000. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21:585-591.
42. Rorden, C. and Brett, M. 2000. Stereotaxic display of brain lesions. Behav. Neurol. 12:191-200.
43. Rose, G.S., Tocco, L.M., Granger, G.A., DiSaia, P.J., Hamilton, T.C., Santin, A.D., and Hiserodt, J.C. 1996. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am. J. Obstet. Gynecol. 175:593-599.
44. Scully, R.E. 1995. Pathology of ovarian cancer precursors. J. Cell. Biochem. 23:208-218.
45. Shih, I.M. and Kurman, R.J. 2005. Molecular pathogenesis of ovarian borderline tumors: New insights and old challenges. Clin. Cancer Res. 11:7273-7279.
46. Testa, J.R., Getts, L.A., Salazar, H., Liu, Z., Handel, L.M., Godwin, A.K., and Hamilton, T.C. 1994. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res. 54:2778-2784.
47. Wadghiri, Y.Z., Schneider, A.E., Gray, E.N., Aristizabal, O., Berrios, C., Turnbull, D.H., and Gutstein, D.E. 2007. Contrast-enhanced MRI of right ventricular abnormalities in CX43 mutant mouse embryos. NMR Biomed. 20:366-374.
48. Ward, B.G., Wallace, K., Shepherd, J.H., and Balkwill, F.R. 1987. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res. 47:2662-2667.
49. Woods, L.K., Morgan, R.T., Quinn, L.A., Moore, G.E., Semple, T.U., and Stedman, K.E. 1979. Comparison of four new cell lines from patients with adenocarcinoma of the ovary. Cancer Res. 39:4449-4459.
50. Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D.R., Akyol, A., Hanash, S., Misek, D.E., Katabuchi, H., Williams, B.O., Fearon, E.R., and Cho, K.R. 2007. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/betacatenin and PI3K/ Pten signaling pathways. Cancer Cell 11:321-333.
51. Xing, D. and Orsulic, S. 2005. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc. Natl. Acad. Sci. U.S.A. 102:6936-6941.
52. Xing, D. and Orsulic, S. 2006. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res. 66:8949-8953.